Cilostazol induced migraine does not respond to sumatriptan in a double blind trial.

ABSTRACT:

Background

Cilostazol is an inhibitor of phosphodiesterase 3 and thus causes accumulation of cAMP. It induces migraine-like attacks in migraine patients. Whether the cilostazol model responds to sumatriptan in migraine patients and therefore is valid for testing of future anti-migraine medications has never been investigated.

Methods

In a cross-over study, 30 patients received cilostazol (200 mg p.o.) on two separate days each day followed by oral self-administered placebo or sumatriptan 50 mg. We recorded headache characteristics and associated symptoms using a questionnaire. The 30 participants were asked to subsequently treat their spontaneous attacks with sumatriptan (50 mg) or placebo in a double-blind cross-over design and 15 participants did so.

Results

Cilosta

SUBMITTER: Falkenberg K 

PROVIDER: S-EPMC5796931 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature